Stay updated on Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial
Sign up to get notified when there's something new on the Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial page.

Latest updates to the Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded a new revision tag (Revision: v3.4.2). Removed an operational status notice about government funding, while the study details and status remain unchanged.SummaryDifference0.4%

- Check21 days agoChange DetectedA new notice warns that information on the site may not be up to date due to a lapse in government funding, with a link to opm.gov for status updates. The page version has been updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedThe changes include a new 'Show glossary' feature and minor label capitalization updates for entries such as 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and the revision label updated to 'Revision: v3.4.0'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check35 days agoChange DetectedThe page revision was updated from v3.3.3 to v3.3.4, indicating a minor update to the page content or formatting.SummaryDifference0.1%

- Check64 days agoChange DetectedLocations now includes Greater London, and the page previously listing 'Greater London Locations' has been removed. The footer item 'HHS Vulnerability Disclosure' has been deleted, and the page revision updated to v3.3.3.SummaryDifference0.2%

- Check85 days agoChange DetectedThe page shows a minor revision from v3.3.1 to v3.3.2; no study content or eligibility criteria have changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial page.